Overview
Primary effusion lymphoma (PEL) is a rare subtype of non-Hodgkin lymphoma characterized by lymphomatous proliferation within body cavities without detectable solid tumor masses, often associated with Human herpesvirus 8 (HHV-8) 1.Diagnosis
Cytopathological examination of body fluid (ascites, pleural fluid) for atypical lymphocytes 1.
Immunohistochemistry and molecular studies to confirm monoclonal B-cell proliferation 1.
Imaging studies (CT, MRI) to assess extent and involvement of body cavities 1.
Serological testing for HHV-8 antibodies may be relevant in some cases 1.Management
First-line treatment typically involves combination chemotherapy regimens such as EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) 1.
Rituximab, an anti-CD20 monoclonal antibody, may be added for B-cell lymphomas 1.
Supportive care including management of ascites and infection control is crucial 1.
For transplant recipients, careful adjustment of immunosuppression is necessary to balance lymphoma treatment efficacy and graft rejection risk 1.Special Populations
Transplant Recipients: Increased risk of developing post-transplant lymphoproliferative disorders (PTLD), including PEL, necessitating vigilant monitoring and tailored immunosuppression strategies 1.Key Recommendations
Closely monitor transplant recipients for signs of PTLD, including PEL, due to heightened immunosuppression risks 1 (Evidence: Expert opinion).
Early cytopathological evaluation of body fluids in suspected cases is essential for timely diagnosis 1 (Evidence: Moderate).
Combination chemotherapy regimens should be considered as first-line treatment, with rituximab potentially added for B-cell lymphomas 1 (Evidence: Moderate).References
1 Testa A, Baiocchini A, Comandini UV, Falasca L, Nardacci R, Maritti M et al.. Fatal sclerosing peritonitis associated with primary effusion lymphoma after liver transplantation: a case report. Transplantation proceedings 2010. link